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Abstract
Three complementary approaches for managing physical and psychological symptoms related to chemotherapy-induced
peripheral neuropathy were evaluated against an education-only control arm. This study included 26 participants who were randomly assigned to weekly, hour-long sessions of yoga, Reiki, meditation, or an educational control experience for 6 weeks. Each
participant completed pre–post measures of neurotoxicity, quality of life, psychological distress, and mindfulness. Descriptive
analysis of the data indicated that all experimental group participants demonstrated improved within-group scores on quality
of life and neurotoxicity outcomes following intervention; however, the improvements were not statistically significant. Neurotoxicity worsened significantly in the control group, but there were no pre–post changes with respect to quality of life, psychological distress, or mindfulness. Effect sizes were large with respect to meditation and mindfulness and with Reiki and psychological
distress. Moderate effect sizes with respect to yoga and neurotoxicity and quality of life offer promise for all 3 interventions in
managing chemotherapy-induced peripheral neuropathy.
Keywords
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Chemotherapy-induced peripheral neuropathy is a side effect
that occurs with many of the most common chemotherapeutic
agents used to treat cancer.1,2 It is the result of damage caused
to the peripheral nervous system by chemotherapy and can affect
sensory, motor, and autonomic neurons.3,4 Chemotherapyinduced peripheral neuropathy can produce sensory symptoms
that range from bothersome to disabling tingling, burning,
numbness, loss of balance, pain, and loss of motor function that
can include weakness in muscles in the upper and lower extremities.5 Although the actual prevalence of chemotherapy-induced
peripheral neuropathy is unknown, it is generally estimated
at 30% to 40% in patients who have received the classes
of chemotherapeutic agents used to treat breast, colon, and
lung cancers, and lymphomas.1,6-8 Typically, symptoms of
chemotherapy-induced peripheral neuropathy are considered
along with other pain symptoms and treated with opioids and
analgesics.9 However, these options yield limited results. With
few alternatives for attenuating the symptoms of unremitting
chemotherapy-induced peripheral neuropathy, people living
with them have few options other than to endure them.
Massage, yoga, and other complementary and alternative
medical modalities have proven successful with pain and
quality-of-life issues related to cancer and its treatment.10-13
Given the limited effectiveness of allopathic intervention, the

purpose of this pilot study was to determine the feasibility of
using 3 complementary interventions in relieving the physical
and emotional symptoms associated with chemotherapyinduced peripheral neuropathy while increasing capacity for
mindfulness or self-focused attention. Of specific interest in
this proposed study are 1 putative energy field or biofield14
approach and 2 complementary mind–body approaches that
include Reiki, yoga, and meditation, respectively.

Reiki
Reiki is a Japanese biofield or energy technique used for
stress reduction, relaxation, and the promotion of physical
healing. As an integrative approach, Reiki is considered
to be a low-risk intervention for enhancing the body’s
1
2
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self-healing capacity with few reports of contraindications or
adverse events.15
Limited research findings indicate that Reiki shows promise for relieving pain from a variety of medical and psychiatric
conditions that include cancer, surgical pain, chronic back
pain, arthritis, depression, and anxiety.16-19 Reiki has also
produced positive results in people receiving treatment for a
variety of local and advanced cancers and has had a significant positive effect on relieving cancer-related fatigue, pain,
anxiety, depression, and contributing to quality of life.20-22
However, research using Reiki in the treatment of
chemotherapy-induced peripheral neuropathy is scant and
only one published descriptive article was located in preparation for this study.23

Yoga
Yoga practice includes muscle stretching and breathing
exercises and helps promote stress control, flexibility, balance, sleep, and voluntary control of the autonomic nervous
system.24-26 Even though the majority of published research
involving yoga and cancer has been conducted with breast
cancer survivors,27,28 studies investigating the use of a yoga
as a complementary and alternative medicine intervention
have reported generally positive physical, psychological, and
quality-of-life outcomes. Yoga has proven helpful as an adjuvant to antiemetic therapy29; in the management of menopausal symptoms30; and in diminishing acute and persistent
cancer related fatigue, diarrhea, and shortness of breath.31-34
Significant positive psychological and quality-of-life outcomes have included decreases in psychological distress,
anxiety, and depression.29,31,35,36

Meditation
Meditation has long been a component of mind–body medicine
for its potential to enhance relaxation, reduce stress, and
improve general medical symptoms.37,38 Mindfulness-based
stress reduction, developed by Kabat-Zinn,39 integrates mindfulness meditation with the healing process and the management of medical and psychological issues. Mindfulness
meditation strategies, including mindfulness-based stress
reduction, have been noted to have a general or nonspecific
stress reducing effects that have proven beneficial both to
healthy subjects and to those living with heart disease,
chronic pain, and emotional disorders.40 Randomized studies
have produced evidence that mindfulness meditation/
mindfulness-based stress reduction interventions have significantly reduced pain, sleep disturbances, anxiety, and depression while simultaneously increasing mindfulness and
quality of life.41,42 Within the general cancer population,
mindfulness meditation/mindfulness-based stress reduction
has produced similar positive results. These have included
reduction in treatment-related insomnia, fatigue, psychological distress, and other mood symptoms.43,44
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Rationale for the Study
There can be no doubt that ever-growing numbers of health
care consumers are choosing complementary and alternative
medicine therapies to address their disease or its effect on quality of life. A study with a large and ethnically diverse random
sample of 9187 citizens of California45 discovered that nearly
66% of the sample had used a complementary and alternative
medicine modality, regardless of health status, in the 12 months
prior to participation in the study. The use of complementary
and alternative medicine treatments as part of an integrated
approach to the management of cancer is growing in popularity
among people living with cancer-related pain and emotional
distress in America and Europe.46-49 Furthermore, in a recent
study of complementary and alternative medicine use among
cancer survivors, 26% of women and 13.7% of men surveyed
indicated the use of at least one complementary and alternative
medicine modality within the year preceding the study.50
Despite the availability of a variety of allopathic therapies
for managing chemotherapy-induced peripheral neuropathy,
complementary and alternative medicine modalities may provide potential options for improving the management of
chemotherapy-induced peripheral neuropathy; however, there
have been few complementary and alternative medicine studies
that specifically address it. Complementary and alternative
medicine modalities may provide additional control of residual
symptoms of chemotherapy-induced peripheral neuropathy;
however, a thorough search of major databases revealed a solitary randomized study that explored the use of acupuncture and
another presented an overview of integrative approaches for
addressing neuropathic pain.51,52 Therefore, the current feasibility study evaluated three adjuvant complementary approaches in
the management of chemotherapy-induced peripheral neuropathy. Because the focus of the study was to evaluate the strengths
of the identified complementary and alternative medicine modalities, it was not designed with sufficient power for producing
statistically significant outcomes and responses to study interventions will be described in terms of overall trends.

Design/Methodology
Using a pretest–posttest comparison group design with random
assignment, this 4-arm pilot study was undertaken to determine
the efficacy of 3 complementary approaches in reducing the
signs and symptoms of chemotherapy-induced peripheral neuropathy in contrast to a structured biopsychosocial holistic education reference arm. Outcomes were quantitatively assessed
through instruments that measured quality of life, neurotoxicity, psychological distress, and mindfulness.
Participants (N ¼ 36) were recruited for the study through
local oncologists’ offices, mailed fliers, an advertisement in the
health section of a large metropolitan newspaper, and a general
announcement in the monthly newsletter of a large cancer support organization. No financial incentive, other than receiving
the complementary and alternative medicine interventions at
no charge, was provided. The institutional review boards in the
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Enrollment

Assessed for eligibility (n=36)

Excluded (n=0)

Randomized (n=36)

Allocated to Education/Control
(n=9)
Received allocated intervention:
(n=9)
Did not receive allocated
intervention: (n=0)

Lost to follow-up: (n=0)
Discontinued intervention
(Dropped out of study – no
reason provided) (n=2)

Analyzed (n=7)
Excluded from analysis: (Did not
complete post-tests) (n=2)

Allocation

Follow-Up

Analysis

Allocated to Meditation intervention
(n=9)
Received allocated intervention
(n=7)
Did not receive allocated
intervention (family crisis)
(n=1)
(Never attended – no reason
provided) (n=1)

Allocated to Reiki intervention
(n=9)
Received allocated intervention
(n=8)
Did not receive allocated
intervention (cancer
recurrence and restarted
chemotherapy) (n=1)

Allocated to Yoga intervention
(n=9)
Received allocated intervention
(n=7)
Did not receive allocated
intervention
(chemotherapy restarted)
(n=1)
Medical concern (n=1)

Lost to follow-up: (n=0)
Discontinued intervention (work
schedule interfered with
participation) (n=1)

Lost to follow-up (n=0)

Lost to follow-up (n=0)

Discontinued intervention (n=0)

Discontinued intervention
(transportation issue) (n=1)
(Dropped out of study – no reason
provided) (n=1)

Analyzed (n=7)

Analyzed (n=7)

Analyzed (n=5)

Excluded from analysis: (Did not
complete post-tests (n=2)

Excluded from analysis: (Did not
complete post-tests (n=2)

Excluded from analysis: (Did not
complete post-tests (n=4)

Figure 1. Study flow diagram

health system through which the study took place and the university where the principal investigator had a faculty appointment approved the study. Following the presentation of study
details, written informed consent documents were obtained
from each participant prior to being included in the study. The
study flow chart is shown in Figure 1.
To be eligible for the study, participants had to be 18 years
old, have persistent symptoms of chemotherapy-induced
peripheral neuropathy lasting 3 months or more, and have completed chemotherapy that included one or more of the taxane,
vinca alkaloid, or platinum classes of chemotherapies for a cancer diagnosis at least three months prior to beginning the study.
Because the researchers did not have access to participants’
medical records, information about chemotherapy-induced peripheral neuropathy symptoms, diagnosis, and treatment were
self-reported. In addition, participants were excluded if they
were actively taking part in one of the complementary modalities offered in this pilot study. A further requirement for eligibility required readiness for physical activity as demonstrated
by responses to the Physical Activity Readiness Questionnaire
for participants aged 18 to 59 years,53,54 the Revised Physical
Activity Readiness Questionnaire for participants aged 60
years and older55-57 or the Physical Activity Readiness Medical
Examination, conducted by a physician for participants who
have physical conditions that required further evaluation.58
Physical readiness was assessed to ensure safe experiences for
participants who may have been randomized into the yoga or

meditation conditions that required some measure of movement or sitting for brief periods. Finally, participants were
required to have an ability to comfortably speak, read, and
understand English, be fully oriented, and possess the capacity
to understand and provide informed consent. After meeting
eligibility criteria; participants provided signed informed consent and completed baseline outcomes measures. It should be
noted that participants who were taking medications for symptoms of chemotherapy-induced peripheral neuropathy were
encouraged to continue doing so and to alert the researchers
if there were changes or additions to their regimens.

Randomization
After completing pretest instruments, participants were
assigned a case number and randomly assigned to 1 of the 3
intervention groups or the holistic education group. Randomization was not masked. However, efforts to conceal allocation
included the use of case numbers and a computer-generated
random numbers table by the lead researcher. Coresearchers
did not take part in the randomization process. Initially, there
were 9 participants in each arm.

Interventions
To minimize the extraneous effects of time, interventions
began within one month of recruitment. Participants took part
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in Reiki, yoga, meditation, or education 1 hour per week for 6
weeks. In addition to the formal outcomes measures, participants were also asked to keep a log of their symptom severity,
time spent in home practice of their intervention modality, and
to make note of experiences that tended to ameliorate or
exacerbate their physical or emotional states. The holistic education group was used as a control group.

Reiki
Five Reiki masters who shared the same training and used similar approaches provided Reiki sessions. The sessions took place
in a quiet room where up to 5 sessions could be conducted simultaneously. Each session was initiated with a brief conversation
between the participant and the Reiki master to establish rapport
and set goals for the session. Following the conversation, the
participant would lie on a massage table, fully clothed, in a
supine position. Working from the head toward the feet, the
practitioner placed their hands either on or above the participant;
pausing for a few moments at 7 designated locations, reflecting
the chakras, to channel energy from their hands to the client.
After reaching the feet, the participant was asked to roll into a
prone position and the process was repeated. On reaching the
feet for a second time, the session was concluded. Participants
were encouraged to record their symptoms in their journals.

Yoga Intervention
Each weekly session involved gradual movement from one
posture or asana, to another in ways that allowed the participants to move at an individual and safe pace. A registered yoga
teacher trained in Hatha Yoga guided all sessions. The 3 stages
of the intervention involved use of breathing and body scanning
to relax the body before beginning movement, then proceeded
from breathing to assuming postures that enabled gentle stretching. The conclusion of the sessions was composed of 10 minutes
of relaxation. Participants maintained a supine position on the
floor or sat comfortably while the yoga teacher guided them in
relaxed breathing systematic muscle relaxation. As the session
concluded, participants were encouraged to practice yoga each
day and record their practice in their journals.

Meditation Intervention
Meditation sessions followed a weekly protocol. The meditation instructor provided a brief overview of what would be
taught during the session as well as addressing participants’
questions, or feedback about their meditative experiences during the preceding week. The remainder of the hour was devoted
to developing meditative skills using a mindfulness meditation
practice. Participants focused on developing attention to the
breath while learning to recognize, acknowledge, accept the
presence of physical sensations or emotions, then to step back,
release the thought or sensation, and refocus attention toward
the breath. Meditative experiences were expanded to include
meditation while walking and eating. At the conclusion of each
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meeting, the meditation instructor encouraged participants to
engage in daily meditation practices and to document their
practice experiences in the practice journal.

Holistic Education
Each week during the study, participants took part in a 1-hour
class that focused on the biological, psychological, and social
components of chemotherapy-induced peripheral neuropathy.
Topics for each session were presented by an oncology nurse
educator, oncology social worker, or registered dietician.
During the first three weeks of the group, participants were presented with basic information about neuroanatomy, effects
of chemotherapy on the peripheral nervous system, and medications typically used in the management of chemotherapyinduced peripheral neuropathy. During weeks 4 and 5,
participants received information about the use of nutrition and
complementary modalities for managing symptoms of
chemotherapy-induced peripheral neuropathy. During the final
meeting of the group, coping strategies for managing the
impact of chemotherapy-induced peripheral neuropathy on
self-image, relationships with others and abilities to perform
activities at home and were presented.

Measures
Psychological distress. The outcome measure for psychological distress was the Brief Symptom Inventory–18.59 This is
an 18-item screening instrument that measures distress on 3
subscales that include somatization, depression, and anxiety.
When combined, the subscales produce a global severity index.
It is the global severity index that provides an overall measure
of psychological distress. A score of 10 and above for men or
13 and above for women indicates psychological distress. The
Brief Symptom Inventory–18 has been found to have good
internal reliability (Cronbach’s a ¼ .89), was written to be
understood at a sixth-grade reading level, and takes approximately 4 minutes to complete.60
Quality of life and neurotoxicity. The outcome measurement
instrument for quality of life was the Functional Assessment
of Cancer Therapies—Gynecologic Oncology Group–Neurotoxicity scale.61 This is a 38-item scale composed of 27 general
questions that comprise an instrument known as the Functional
Assessment of Cancer Therapies–General. The questions
explore general dimensions of life quality with respect to physical, functional, emotional, social, and family well-being. The
Functional Assessment of Cancer Therapies—Gynecologic
Oncology Group–Neurotoxicity scale combines these questions with 11 questions regarding symptoms of neurotoxicity
to form a neurotoxicity subscale. Using a 5-item Likert-type
scale, respondents rate the degrees to which items were important to them during the past 7 days. Ratings of experiences range
from not at all to very much. This instrument has high test–retest
reliability, consistently high convergent/divergent validity coefficients, and is sensitive to respondent performance status
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rating.61 Although originally developed within the context
of gynecological cancers, this instrument has been used to
measure the side effects of taxane therapy and in colon cancers with both men and women.62,63 Cronbach’s coefficient
for each item on this scale has been demonstrated at .70 or
higher, and the instrument is sensitive to respondent changes
over time.64
Mindfulness. As a component of general well-being, the construct of mindfulness was measured with a scale known as the
Mindful Attention Awareness scale.65 The Mindful Attention
Awareness Scale is a 15-item scale that is self-administered,
requires no assistance to complete, and can be taken in 5 minutes or less. Internal reliability of items on the Mindful Attention Awareness Scale has been established with Cronbach’s a
coefficients at .80 or higher per item,65 and there are no differences in performance on the Mindful Attention Awareness
Scale between men and women.66 The Mindful Attention
Awareness Scale has demonstrable construct validity across
cancer populations with reliability coefficients of .80 or
greater.67
In addition to the above measures, the participants provided
data from a brief sociodemographic data and health history
questionnaire. This information included the participant’s age,
gender, marital status, number of children, and current work
status. In addition, the questionnaire asked about cancer history, including type of cancer, stage of cancer, time since initial
diagnosis, types of cancer treatments received, and last date of
cancer treatment. With the exception of the sociodemographic
data and health form, which was administered once; participants completed study instruments prior to the first experience
in both intervention or control conditions and immediately following their last experience with the study.

Data Analysis
Descriptive analyses were used to articulate demographic and
health characteristics of the study participants, attrition rate,
and adherence to study protocol. One-way analysis of variance
(ANOVA) was used to test for differences between the intervention and control groups. Because the data were collected
using random assignment, paired samples t tests were used to
assess within-group differences for the whole sample as well
as within intervention and control groups. All participants who
completed posttest instruments, regardless of adherence to the
study protocol, were included in the analysis to yield treatment
effects that are reflective of real-world conditions.68 Because
the sample size was small, missing values were replaced with
the series mean for the variable.69,70 A P value <.05 was considered statistically significant.

Results
Sample
Thirty-six participants were initially recruited and randomized
into the study and 31 were present at the first intervention
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sessions. Five of the initial 36 participants were unable to participate. Two of these reported that their cancer had recurred
and required further treatment; making them ineligible to participate. One participant decided to withdraw from the study
following a family emergency and another, after randomization
to the yoga intervention, withdrew on medical advice. Two
participants in the meditation arm began the study but
stopped attending after 2 or 3 meetings. One reported that
it had become difficult to attend an evening group and the
other gave no reason for discontinuing. Two additional participants in the control arm dropped out of the study and did
not provide a reason or respond to attempts at contact. One
member in the Reiki arm withdrew from the study and
reported that her work schedule did not allow for continued participation. The data were analyzed using one-way ANOVA for
assessing between-group comparisons at pretest and posttest.
Comparisons of demographic, health, and outcomes measures
revealed no significant differences between participants who
completed the study and those who did not. At the conclusion
of the intervention phase of the study, 26 participants remained
in the study and completed posttesting following their participation in 1 of the 4 arms that included meditation (n ¼ 5), Reiki
(n ¼ 7), yoga (n ¼ 7), or education (n ¼ 7).
Demographic and clinical characteristics. Of those who elected
to remain in and complete the study, 23 were women (88.5%)
and 3 were men (11.5%) with a median age of 60 years
(range ¼ 38-72 years; Table 1). Nearly 81% of the participants
self-identified as European American or white (n ¼ 21; 80.8%)
and more than three quarters of participants indicated that they
were married (n ¼ 20; 76.9%). Most participants reported having received bachelor’s and advanced degrees (n ¼ 23; 88.5%).
The most frequently reported cancer diagnoses included breast
(n ¼ 17; 65.4%), ovarian (n ¼ 2; 7.7%), and non-Hodgkin lymphoma (n ¼2; 7.7%; Table 2). More than two thirds of participants reported the onset of symptoms of neuropathy during
the course of their chemotherapy treatment (n ¼ 18; 69.2%)
with one third reporting the onset of symptoms following
treatment (n ¼ 8; 30.8%; Table 2). More than one third of participants (n ¼ 10; 38.5%) reported having symptoms of
chemotherapy-induced peripheral neuropathy for more than
2 years, whereas 7 (26.9%) had experienced symptoms for
13 to 24 months, and 9 (34.6%) described having symptoms
for 12 months or less (Table 3). A one-way ANOVA was used
to test for differences between intervention groups. There
were no significant differences between the groups with
respect to demographic or medical characteristics for the
preintervention-dependent measures for psychological distress, neurotoxicity, quality of life, or mindfulness.
Protocol adherence. All 26 participants attended at least one
session of the intervention to which they had been assigned.
Twelve participants (40%) attended all 6 sessions, 8 (26.7%)
attended 5 sessions, 5 (16.7%) attended 4 sessions, 1 (3.3%)
attended 3 sessions, 2 (6.7%) attended 2 sessions, and
2 (6.7%) attended only 1 session. In the meditation arm,
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Table 1. Demographic Variables (N ¼ 26)
Sample (N ¼ 26)
Nominal Variables
Gender
Female
Male
Race
African American
Asian/Pacific Islander
European
European American (white)
Marital status
Single
Married
Partnered
Divorced
Education completed at
Technical school
College courses
Bachelor’s degree
Master’s degree
Doctorate
Age
Group
Full sample

n

Percentage

23
3

88.5
11.5

2
1
1
21

7.7
3.8
3.8
80.8

3
20
1
2

11.5
76.9
3.8
7.7

1
2
13
8
2

3.8
7.7
50.0
30.8
7.7

N
26

Mean
59.04

Table 2. Health Variables

Cancer diagnoses
Ovarian
Colon
Breast
Appendiceal
Non-Hodgkin lymphoma
Brain
Peritoneal
Hodgkin lymphoma
Cancer stage at diagnosis
Stage I
Stage II
Stage III
Stage IV
Unknown
Current diagnostic status
No evidence of disease
Recurrent disease
Metastatic disease
Time since diagnosis
<12 months
>12 months
Onset of neuropathy symptoms
During chemotherapy
Following chemotherapy

SD
8.56

Range
34.00

Skewness
0.456

Kurtosis
0.015

Table 3. Months Living With Chemotherapy-Induced Peripheral
Neuropathy Symptoms

(N ¼ 26)

Percentage

2
1
17
1
2
1
1
1

7.7
3.8
65.4
3.8
7.7
3.8
3.8
3.8

5
4
2
7
8

19.2
15.4
7.7
26.9
11.5

attended 5 sessions, and 1 (14.3%) completed 4 sessions. In
the yoga arm, 2 participants (28.6%) were present for all 6
sessions, 2 (28.6%) attended 5 sessions, 2 (28.6%) attended
4 sessions, and 1 participant (14.3%) attended only 1 session.
In the control condition, which consisted of holistic education, 5 participants (71.4%) attended all 6 sessions and 2
(28.6%) attended 5 sessions.

23
1
2

88.5
3.8
7.7

Psychological Distress

4
22

15.4
84.6

18
8

69.2
30.8

1 participant (20%) attended all 6 sessions, 3 (60%) attended 5
sessions, and 1 (20%) attended 4 sessions. Four members
(57.1%) in the Reiki arm attended all 6 sessions, 2 (28.6%)

Full sample
12 months
13-24 months
>24 months

n

Mean

Median

SD

Range

Skewness

Kurtosis

26
9
7
10

33.12
8.89
18.14
65.40

16.00
10.00
18.00
48.00

35.93
2.67
4.71
40.56

147
7
11
122

2.14
0.20
0.29
1.43

4.69
1.74
1.92
1.24

At pretest, the full-sample mean for psychological distress was
13.84 with 56.5% (n ¼ 13) of women participants scoring
within the clinical range (Table 4). None of the men scored
within the clinical range for psychological distress. At posttest,
the full sample mean for the Brief Symptom Inventory–18 was
diminished to 11.65 (P ¼ .226). A one-way ANOVA was conducted to compare the effect of each of the interventions on
levels of psychological distress, F(3, 22) ¼ 1.15, P ¼ .351.
There was no significant effect of any of the interventions
at the P  .05 level on psychological distress.
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Table 4. Psychological Distress: Brief Symptom Inventory–18 Global
Severity Index
Pretest

Posttest

Pretest

Group

n

Mean

SD

Mean

SD

t

P

Cohen’s d

Full sample
Yoga
Meditation
Reiki
Education

26
7
5
7
7

13.64
15.86
8.75
20.14
8.43

8.95
9.92
3.76
9.72
4.96

11.65
10.71
9.60
17.14
8.57

9.48
9.29
6.91
12.88
6.32

1.240
1.340
0.246
0.764
0.127

.226
.215
.818
.474
.903

0.26
0.16
0.85

Table 5. Neurotoxicity Scale: Functional Assessment of Cancer
Therapies—Gynecologic Oncology Group–Neurotoxicity
Pretest

Table 6. Quality of Life: Functional Assessment of Cancer Therapies—
Gynecologic Oncology Group

Group

n

Mean

SD

Mean

SD

Mean

SD

t

P

Cohen’s d

Full sample
Yoga
Meditation
Reiki
Education

26
7
5
7
7

28.43
30.31
28.50
23.71
31.14

7.71
4.98
3.76
10.16
8.47

28.96
32.43
29.60
26.14
27.86

8.00
3.55
5.59
10.57
9.82

0.55
1.19
0.36
1.53
2.67

.586
.278
.738
.177
.037

0.62
0.22
0.17

Scores on the Brief Symptom Inventory–18 were diminished for participants in the yoga (P ¼ .215) and Reiki arms
(P ¼ .474), but increased in the meditation (P ¼ .818) and education/control (P ¼ .903) arms. It should be noted, however, that
although scores increased in the 2 groups, neither group had
clinically significant scores. Effect sizes for yoga and meditation
conditions indicated a small effect. However, the magnitude of
treatment effect was large in the Reiki condition. Converting
Cohen’s d to r2 shows that 15% of the variation was attributable
to the Reiki intervention.

SD

t

P

Cohen’s d

17.60
11.46
17.58
21.47
20.25

1.260
0.675
0.087
2.092
0.068

.221
.525
.935
.081
.948

0.40
0.15
0.21

Table 7. Mindfulness: Mindful Attention Awareness Scale
Pretest

n

Mean

Full sample 26 106.80 17.46 110.24
Yoga
7 112.10 18.90 116.80
Meditation
5 106.50 8.22 107.30
Reiki
7 98.17 21.04 105.80
Education
7 110.31 17.04 110.17

Posttest

Group

Posttest

Posttest

Group

n

Mean

SD

Mean

SD

t

P

Cohen’s d

Full sample
Yoga
Meditation
Reiki
Education

26
7
5
7
7

3.94
4.02
4.62
3.39
4.10

0.888
1.150
0.626
0.770
0.685

4.00
4.04
4.73
3.48
3.96

0.953
0.971
0.812
0.950
0.760

0.611
0.081
0.412
0.755
.580

.547
.938
.702
.479
.583

0.09
0.98
0.56

One-way ANOVA revealed that no significant effect on quality
of life at the P < .05 level for any of the 3 study interventions,
F(3, 22) ¼ 0.490, P ¼ .693. Paired samples t-test results for
within-group results revealed that, although scores were
improved, they were not statistically significant. A weak to
moderate effect size was noted in the yoga intervention, but
when Cohen’s d was converted to r2, only 3.9% of the variance
was attributable to the intervention. Pre–post change in the control arm was negligible.

Mindfulness
Neurotoxicity and Quality of Life
Symptoms of neurotoxicity improved, as indicated by higher
scores, only slightly in the full sample from 28.43 to 28.96
(Table 5). However, a one-way ANOVA indicated that there
was no significant effect of any of the interventions on symptoms of neurotoxicity, F(3, 22) ¼ 0.76, P ¼ .529. With the
exception of the control group, no statistically significant differences were found within groups in any of the study arms
with respect to neurotoxicity or quality of life. Cohen’s d for
meditation and Reiki was small; however, a moderate effect
size was found in the yoga intervention. Converting Cohen’s
d to r2 shows that 8.7% of the variation was attributable to the
yoga intervention. Although each study arm demonstrated
improvement on the neurotoxicity subscale, the control arm
demonstrated a significantly poorer pre–post result from
31.14 to 27.86 (P ¼ .034).
The mean Functional Assessment of Cancer Therapies—
Gynecologic Oncology Group–Neurotoxicity scale score on
quality-of-life items for the full sample at pretest was 106.8 and
this score improved at posttest to 110.24 (Table 6). In each arm,
with the exception of the control arm, improvement was noted.

One-way ANOVA revealed that none of the interventions
appears to have had a statistically significant effect on mindfulness or capacity to attend to events in the present moment as a
method for self-regulation, F(3, 22) ¼ 1.966, P ¼ .149. Little
change was noted in the full sample mean between pretest
(3.96) and posttest (4.05; Table 7). The within-group scores
reflected similar results. Effect size for the meditation arm indicated that the magnitude of the treatment effect was large. Converting Cohen’s d to r2 shows that 19.3% of the variation was
attributable to the meditation intervention.

Compliance at Home
Per study protocol, participants were asked to maintain a daily
log of the time spent practicing the intervention they were
learning. Practicing was defined for participants as engaging
in an activity learned while taking part in their intervention.
Participants could practice yoga postures, engage in meditation, remember a positive experience during Reiki, or review
class materials presented in the education/control condition.
Twenty-four of the 26 participants submitted logs for analysis.
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In the full sample, total days of practice ranged from 0 to 36
days yielding a mean of 10.58 days. Similarly, actual minutes
of practice ranged from 0 to 1301 minutes yielding an average
of 313.68 minutes of practice, or less than 10 minutes per day,
over the course of the 6-week study. All participants in the
meditation intervention (n ¼ 5) reported practicing meditation
during the study with a mean of 22.2 days of practice for 25
minutes per day. Similarly, 5 members of the yoga intervention
(n ¼ 7) engaged in daily practice with a mean of 18 days of
practice for an average of 14 minutes per day. Although participants in the Reiki condition (n ¼ 7) did not learn a specific
symptom management technique, 3 engaged in reflections
about their experiences in the study for 5 days on average during the study for 17 minutes each day. Perhaps not surprisingly,
only one member in the education/control condition reported
review of class materials on 4 days during the study and for less
than 2 minutes per day.

Discussion
In the current pilot study, 3 complementary and alternative
medicine modalities that included Reiki, yoga, and meditation
were evaluated for their feasibility in managing the physical
and psychological sequelae of chemotherapy-induced peripheral neuropathy. From the review of existing literature, each
of the modalities examined for this study had been shown to
have beneficial outcomes with respect to symptom management in people living with cancer and chronic illness. Although
this pilot study did not produce results that identified greater
effectiveness among the interventions studied; it yielded promising results suggesting that complementary and alternative
medicine modalities may improve patient outcomes with
respect to psychological distress, quality of life, and neurotoxicity in people living with chemotherapy-induced peripheral
neuropathy. In addition, the primary findings included (a)
reduction of levels of psychological distress in participants in
the yoga and meditation interventions, (b) increased quality
of life in all intervention arms, and (c) reduction of neurotoxicity symptoms in all intervention arms with significant worsening of symptoms within the control arm.
Following an extensive review of the literature, we have
concluded that this pilot study may be the first to examine the
use of Reiki, yoga, or meditation in the chemotherapyinduced peripheral neuropathy population. Furthermore,
the findings of this study are consistent with reviews of other
controlled studies involving the use of Reiki, yoga, or mindfulness meditation.27,28,71
A thorough examination of 66 peer-reviewed studies involving Reiki and other biofield therapies in the treatment of a variety of physical conditions found moderate to strong support for
evidence that demonstrated the reduction of pain intensity;
however, evidence for improvement of quality of life and amelioration of fatigue was much weaker.72 Within the cancer population, a review of 10 studies that included 6 randomized
controlled trials found that following yoga-based interventions
participants experienced improvements in stress, quality of life,
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and sleep.28 A thoroughgoing meta-analysis of 10 randomized
controlled trials by Lin et al27 mirrored the aforementioned
study with significant improvement reported following yoga
interventions in cancer populations with respect to levels of
anxiety, depression, stress, and distress. However, the effectiveness of the yoga interventions in both reviews could not
be determined as a result of variability between the studies and
methodological issues.27,28 Finally, in a well-crafted review of
52 randomized controlled trials studies that examined the neurobiological, biochemical, and clinical effects of meditation,
Chiesa and Serretti40 found that, in addition to neurobiological
changes, meditation helped ameliorate the symptoms of physical and mental conditions from hypertension and fibromyalgia
to depression and substance dependence.
The study has strengths and limitations that must be
acknowledged. Particularly strong components of this study
included the diligent attention to design and monitoring of the
study, process for random assignment of participants, inclusion
of an educational control group, use of trained practitioners,
and selection of instruments that were well validated and
reflected the targeted outcomes.
Limitations of the study included issues related to sample
size and related methodological issues. Recruitment was slow
and time constraints prevented development of a larger sample.
In addition temporal issues, notably conducting the study in
late spring, may have had an impact in adherence as participants began scheduling holidays in lieu of participation. Several positive results emerged from this study; however, the
small sample size of just 26 participants and the concomitant
lack of power limits the extent to which any of the modalities
studied can be regarded as effective for managing the physical
and psychological symptoms associated with chemotherapyinduced peripheral neuropathy. Furthermore, the limited sample size also restricted options for complex research design
strategies. Thus, in retrospect, we might have considered limiting the number of interventions to 2 rather than 3 interventions
and a control group. This might have improved our outcomes.

Conclusion
Chemotherapy-induced peripheral neuropathy is difficult to
manage and allopathic treatment options rarely provide total
relief from symptoms that interfere with physical and emotional functioning. Complementary and alternative medicine
options may provide complementary or adjuvant alternatives
to traditional models of treatment for chemotherapy-induced
peripheral neuropathy.
Research exploring the use of complementary and alternative medicine interventions in the amelioration of cancerrelated physical and psychological distress is in its beginning
stages. However, findings within the body of research have
been positive and, combined with the findings of this pilot
study, indicate that there is an appropriate role for Reiki, yoga,
and meditation in the management of chemotherapy-induced
peripheral neuropathy. The potentially beneficial physical and
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psychological changes that emerged from this study warrant
further well-defined clinical investigation.
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